CClinicalTrials.gg
CompletedNCT02814682QUALI-PALLIUpdated Jun 28, 2016

Elaboration of a Multi-dimensional Indicator of Quality in Palliative Care

An observational study in Terminal Illness and End of Life, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-28.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

Study type
Observational
Time perspective
Retrospective
Enrollment
560
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to elaborate a multi-dimensional indicator of the quality in palliative care for patients of end-of-life.

The study will, as secondary objectives:

  • elaborate in a standard manner one set of indicators of organization and inner working of a palliative care setting.
  • compare according to these indicators, the qualities of 3 types of palliative care: palliative care unit in hospitals, specified identified bed for palliative care patients and non-specified bed.
  • explore the relationship between organizational aspects and results in term of burden.
Read the detailed description

A multicentric study aims on quality of palliative care and will be conducted in three types of 7 palliative care settings: two hospices, two hospital-based palliative care units and three medical units where a mobile palliative care team intervenes.

02

Conditions studied

  • Terminal Illness
  • End of Life

Browse trials for

Keywords

  • palliative care
  • quality
  • indicator
  • multi-dimensional
03

In context

Death

572 studies on the registry are indexed under Death; 111 are open to participants now.

This study's enrollment of 560 is above the median of 314 across 293 observational studies indexed under Death.

Browse Death studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study population:

  • Patients on palliative care phase,
  • Family members or other people present beside patients,
  • Caregivers (physicians, nurses) who care patients.

Inclusion criteria

  • Aged ≥ 18 years.
  • Patient with serious progressive illness and in terminal phase (life expectancy \< 3 months): OMS stage is 3 or 4, regardless of etiology.
  • Patient informed their diagnosis or not.
  • Hospitalized at the moment of inclusion in one of the following care settings: palliative care unit, identified bed or non-identified bed in a care department of short stay.
  • No-oppose to participate to the study, by patients, their families or trusted person.

Exclusion criteria

Exclusion Criteria:

  • Patient has difficulties in reading, writing or understanding french language, also their family.
  • Hospitalization in the palliative care setting \< 48 hours.
05

Study design

Time perspective
Retrospective
Enrollment
560 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Questionnaire for patients

    A questionnaire has been elaborated beforehand by the study will be answered by patients in order to evaluate quality such as reliability, dimensionality and validity against criterion.

    Time frame: From date of enrollment until the date of first documented leaving from hospital or date of death, whichever came first, up to 2 years

  2. Indicator for medical files

    The indicators have been defined by the study, in order to evaluate quality of medical files, such as completeness and discriminatory capacity.

    Time frame: At enrollment

  3. Indicator for caregivers

    In order to evaluate quality such as reliability and dimensionality, a questionnaire will be answered by caregivers: - the Nursing Stress Scale (NSS).

    Time frame: From date of enrollment until the date of receiving questionnaire returned by caregiver, up to 2 years

  4. Questionnaire for families

    A questionnaire has been elaborated, will be answered by patients' families.

    Time frame: From date of enrollment until the date of receiving questionnaire sent by family, up to 2 years

07

Study locations

1 site
  • Maison Médicale Jeanne Garnier
    Paris, Ile de France 75015, France
08

References and documents

Publications

  • Guirimand F, Martel-Samb P, Guy-Coichard C, Picard S, Devalois B, Copel L, Abel A, Ghadi V; QUALI-PALLI group and Philippe Aegerter. Development and validation of a French questionnaire concerning patients' perspectives of the quality of palliative care: the QUALI-PALLI-Patient. BMC Palliat Care. 2019 Feb 11;18(1):19. doi: 10.1186/s12904-019-0403-z. PubMed 30744627 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02814682
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Responsible party
Sponsor
First posted
Jun 28, 2016
Start date
Dec 2012
Primary completion
May 2014
Completion
May 2014
Last update
Jun 28, 2016

Study contacts

Frédéric GUIRIMAND, MD
study chair · Maison Médicale Jeanne Garnier
Philippe Aegerter, MD, PhD
study director · Hôpital Ambroise Paré, AP-HP

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion